CTI BioPharma (NASDAQ:CTIC) reported Q1 EPS of ($0.37), $0.04 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $13 million.
CTI BioPharma (NASDAQ:CTIC) reported Q1 EPS of ($0.37), $0.04 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $2.3 million versus the consensus estimate of $13 million.